Advertisement

Topics

FluGen Completes Dosing of Phase 2 Study to Assess Effectiveness of Novel Influenza Vaccine Designed to Protect Against Mismatched Strains

09:00 EDT 15 Oct 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
—Influenza challenge virus genetically drifted by six years from vaccine strain— FluGen, Inc. announced today that all subjects have completed dosing in a first-of-its-kind clinical study which challenged subjects with a...

Other Sources for this Article

For FluGen, Inc.
John Bluth
+1 650 799 6612
jbluth@jdbcommunications.com

NEXT ARTICLE

More From BioPortfolio on "FluGen Completes Dosing of Phase 2 Study to Assess Effectiveness of Novel Influenza Vaccine Designed to Protect Against Mismatched Strains"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...